Details for Patent: 8,101,743
✉ Email this page to a colleague
Which drugs does patent 8,101,743 protect, and when does it expire?
Patent 8,101,743 protects TEGSEDI and WAINUA (AUTOINJECTOR) and is included in two NDAs.
Summary for Patent: 8,101,743
Title: | Modulation of transthyretin expression |
Abstract: | Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided. |
Inventor(s): | Brown-Driver; Vickie L. (Solana Beach, CA), Jain; Ravi (Fremont, CA) |
Assignee: | Isis Pharmaceuticals, Inc. (Carlsbad, CA) |
Application Number: | 12/273,731 |
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,101,743
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Akcea Theraps | TEGSEDI | inotersen sodium | SOLUTION;SUBCUTANEOUS | 211172-001 | Oct 5, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |